These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7552742)

  • 41. Mechanisms of anticoagulant effects of some sulphated polysaccharides.
    Andersson LO; Hoffman J; Holmer E; Larm O; Larsson K; Söderström G
    Thromb Res; 1982 Dec; 28(6):741-7. PubMed ID: 6132465
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sequence determination and anticoagulant and antithrombotic activities of a novel sulfated fucan isolated from the sea cucumber Isostichopus badionotus.
    Chen S; Hu Y; Ye X; Li G; Yu G; Xue C; Chai W
    Biochim Biophys Acta; 2012 Jul; 1820(7):989-1000. PubMed ID: 22446377
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors.
    Buckman BO; Mohan R; Koovakkat S; Liang A; Trinh L; Morrissey MM
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2235-40. PubMed ID: 9873520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sugars slide into heparin activity.
    Sinaÿ P
    Nature; 1999 Apr; 398(6726):377-8. PubMed ID: 10201366
    [No Abstract]   [Full Text] [Related]  

  • 45. Impact of autoclave sterilization on the activity and structure of formulated heparin.
    Beaudet JM; Weyers A; Solakyildirim K; Yang B; Takieddin M; Mousa S; Zhang F; Linhardt RJ
    J Pharm Sci; 2011 Aug; 100(8):3396-3404. PubMed ID: 21416466
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structural and functional properties of heparin analogues obtained by chemical sulphation of Escherichia coli K5 capsular polysaccharide.
    Razi N; Feyzi E; Björk I; Naggi A; Casu B; Lindahl U
    Biochem J; 1995 Jul; 309 ( Pt 2)(Pt 2):465-72. PubMed ID: 7626010
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of a heparan sulphate with high affinity for antithrombin III upon inactivation of thrombin and coagulation factor Xa.
    Scully MF; Ellis V; Shah N; Kakkar V
    Biochem J; 1989 Sep; 262(2):651-8. PubMed ID: 2529852
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site.
    Petitou M; Casu B; Lindahl U
    Biochimie; 2003; 85(1-2):83-9. PubMed ID: 12765778
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of new synthetic heparin mimetics.
    Hérault JP; Bernat A; Roye F; Michaux C; Schaeffer P; Bono F; Petitou M; Herbert JM
    Thromb Haemost; 2002 Jun; 87(6):985-9. PubMed ID: 12083506
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanism of potentiation of antithrombin III and heparin cofactor II inhibition by sulfated xylans.
    Carson L; Doctor VM
    Thromb Res; 1990 May; 58(4):367-81. PubMed ID: 1972302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma.
    Ofosu FA; Choay J; Anvari N; Smith LM; Blajchman MA
    Eur J Biochem; 1990 Oct; 193(2):485-93. PubMed ID: 2226466
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pre-clinical pharmacological profile of the novel glycoconjugate Org 36764 with both factor Xa and thrombin (IIa) inhibitory activities.
    Vogel GM; van Amsterdam RG; van Dinther TG; Tromp M; Meuleman DG
    Thromb Haemost; 2000 Oct; 84(4):611-20. PubMed ID: 11057859
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by promoting the assembly of an intermediate heparin-antithrombin-factor Xa bridging complex. Demonstration by rapid kinetics studies.
    Rezaie AR; Olson ST
    Biochemistry; 2000 Oct; 39(39):12083-90. PubMed ID: 11009624
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A mechanism for heparin-induced potentiation of antithrombin III.
    van Boeckel CA; Grootenhuis PD; Visser A
    Nat Struct Biol; 1994 Jul; 1(7):423-5. PubMed ID: 7664058
    [No Abstract]   [Full Text] [Related]  

  • 55. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chemical synthesis and pharmacological properties of heparin pentasaccharide analogues.
    Zhou Z; Zhang L; Wu X; Luo L; Wu J; Xu D; Wu M
    Eur J Med Chem; 2022 Apr; 234():114256. PubMed ID: 35279609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A kinetic study on the effects of anticoagulants on the interaction of fibrinogen and thrombin.
    Nakanishi E; Sato H; Nakajima A
    J Biomed Mater Res; 1987 Feb; 21(2):187-200. PubMed ID: 2434508
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dracula's wish.
    Peters R; Sikorski R
    Science; 1999 May; 284(5418):1294. PubMed ID: 10383310
    [No Abstract]   [Full Text] [Related]  

  • 59. Monitoring complex formation in the blood-coagulation cascade using aptamer-coated SAW sensors.
    Gronewold TM; Glass S; Quandt E; Famulok M
    Biosens Bioelectron; 2005 Apr; 20(10):2044-52. PubMed ID: 15741074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ratios of anti-factor Xa to antithrombin activities of heparins as determined in recalcified human plasma.
    Schoen P; Lindhout T; Hemker HC
    Br J Haematol; 1992 Jun; 81(2):255-62. PubMed ID: 1322691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.